BA
MDGL icon

Bridgewater Associates’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bridgewater Associates’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.05M Sell
3,920
-15,298
-80% -$7.31M 0.01% 653
2025
Q4 		$11.2M Sell
19,218
-8,567
-31% -$4.38M 0.04% 327
2025
Q3 		$12.7M Buy
+27,785
New +$10.4M 0.05% 285

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgewater Associates's MDGL Position: Q1 2026 in Review

Bridgewater Associates reduced its Madrigal Pharmaceuticals (MDGL) stake by 80% in Q1 2026, selling an estimated $7.31M and leaving 3,920 shares worth $2.05M. The position accounts for 0.01% of the portfolio, ranked #653.

Bridgewater Associates first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. The position peaked at $12.7M in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Bridgewater Associates held 3,920 shares of Madrigal Pharmaceuticals worth $2.05M as of Q1 2026.
  • Bridgewater Associates sold 15,298 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $7.31M.
  • Madrigal Pharmaceuticals made up 0.01% of Bridgewater Associates's portfolio in Q1 2026, its #653 holding.
  • Bridgewater Associates first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Bridgewater Associates's Madrigal Pharmaceuticals position peaked at $12.7M in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.